Cheryl Kunis is a Nephrology physician affiliated with Columbia University. OpenAlex indexes 20 publications with 2,735 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11e 26th St 1302
New York, NY 100101432
Telephone
646-438-9654Registry record last updated 20 Sept 2015.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fisher & Paykel Healthcare LimitedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
27.2%Insulin Analog12.8%Lantus Solostar52%Humalog Kwikpen U-10048%Part D<11 patientsSGLT2 inhibitor7.7%Jardiance100%Part D<11 patients+ 1 more class in this area
Cardiovascular
22.1%Angiotensin receptor blocker (ARB)12.3%Losartan Potassium100%Part D<11 patientsStatin9.7%Atorvastatin Calcium100%Part D<11 patientsMusculoskeletal
20.5%Xanthine oxidase inhibitor20.5%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1997–2000 per NIH RePORTER. The latest:
- PLACEBO CONTROLLED SAFETY AND EFFICACY STUDY OF PIMAGEDINE--TYPE II DIABETES
Columbia University Health Sciences
FY2000$121,168M01RR000645 - PLACEBO CONTROLLED SAFETY AND EFFICACY STUDY OF PIMAGEDINE--TYPE II DIABETES
Columbia University Health Sciences
FY1999M01RR000645 - PLACEBO CONTROLLED SAFETY AND EFFICACY STUDY OF PIMAGEDINE--TYPE II DIABETES
Columbia University Health Sciences
FY1999M01RR000645
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Beneficial Effect of Rituximab in the Treatment of Recurrent Idiopathic Membranous Nephropathy after Kidney Transplantation
Clinical Journal of the American Society of Nephrology
2010 - Development of Focal Segmental Glomerulosclerosis after Anabolic Steroid Abuse
Journal of the American Society of Nephrology
2009 - Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury
Journal of Clinical Investigation
2005
Similar KOLs
Other experts from the same institution or the same specialty.
Serge Przedborski, MD, PhD
Columbia University
Shonni Silverberg, MD
Columbia University
Mitchell Benson, MD
Columbia University
Andrew Lassman, MD
Columbia University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”